Prelude Therapeutics Inc financial data

Symbol
PRLD on Nasdaq
Location
175 Innovation Boulevard, Wilmington, DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 442 % -51.8%
Debt-to-equity 42.7 % +110%
Return On Equity -121 % -81.1%
Return On Assets -84.9 % -52.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.9M shares +14.2%
Entity Public Float 66.1M USD -14.3%
Weighted Average Number of Shares Outstanding, Basic 76.1M shares +0.36%
Weighted Average Number of Shares Outstanding, Diluted 76.1M shares +0.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 6.5M USD +117%
Research and Development Expense 108M USD -7.52%
General and Administrative Expense 23.6M USD -20.1%
Operating Income (Loss) -121M USD +15.5%
Net Income (Loss) Attributable to Parent -112M USD +15%
Earnings Per Share, Basic -1 USD/shares +17%
Earnings Per Share, Diluted -1 USD/shares +17%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 47.5M USD +327%
Marketable Securities, Current 7.43M USD -94.8%
Assets, Current 58.3M USD -62.7%
Property, Plant and Equipment, Net 5.53M USD -23.2%
Operating Lease, Right-of-Use Asset 27.5M USD -5.6%
Assets 94.8M USD -52%
Accounts Payable, Current 2.53M USD -57.2%
Employee-related Liabilities, Current 6.49M USD -14.6%
Accrued Liabilities, Current 12.9M USD -4.78%
Liabilities, Current 18.2M USD -18.2%
Operating Lease, Liability, Noncurrent 15.1M USD -1.85%
Other Liabilities, Noncurrent 2.9M USD -7.9%
Liabilities 36.2M USD -11.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2K USD -98.8%
Retained Earnings (Accumulated Deficit) -667M USD -20.1%
Stockholders' Equity Attributable to Parent 58.5M USD -62.6%
Liabilities and Equity 94.8M USD -52%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.2M USD -7.68%
Net Cash Provided by (Used in) Financing Activities -160K USD
Net Cash Provided by (Used in) Investing Activities 62.2M USD +99.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 27.8M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 50.8M USD +234%
Deferred Tax Assets, Valuation Allowance 183M USD +23.7%
Deferred Tax Assets, Gross 188M USD +23%
Operating Lease, Liability 17.9M USD +0.43%
Payments to Acquire Property, Plant, and Equipment 47K USD -83.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -112M USD +14.4%
Lessee, Operating Lease, Liability, to be Paid 39.5M USD -6.29%
Property, Plant and Equipment, Gross 12M USD +10.4%
Operating Lease, Liability, Current 2.73M USD +15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.05M USD +2.28%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.97M USD +8.27%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21.6M USD -11.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.12M USD +2.29%
Deferred Tax Assets, Operating Loss Carryforwards 81.5M USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.2M USD +2.3%
Operating Lease, Payments 620K USD
Depreciation, Depletion and Amortization 435K USD +2.11%
Deferred Tax Assets, Net of Valuation Allowance 5.02M USD +0.04%
Share-based Payment Arrangement, Expense 13.8M USD -41.1%